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Background: Dynamic left ventricular (LV) outflow tract (LVOT) obstruction (DLVOTO) is not infrequently observed
in older individuals without overt hypertrophic cardiomyopathy (HCM). We sought to investigate associated
geometric changes and then evaluate their clinical characteristics.
Methods: A total of 168 patients with DLVOTO, which was defined as a trans-LVOT peak pressure gradient (PG)
higher than 30 mmHg at rest or provoked by Valsalva maneuver (latent LVOTO) without fixed stenosis, were
studied. Patients with classical HCM, acute myocardial infarction, stress induced cardiomyopathy or unstable
hemodynamics which potentially induce transient-DLVOTO were excluded.
Results: Their mean age was 71 ± 11 years and 98 (58%) patients were women. Patients were classified as pure
sigmoid septum (n = 14) if they have basal septal bulging but diastolic thickness less than 15 mm, sigmoid septum
with basal septal hypertrophy for a thickness ≥15 mm (n = 85), prominent papillary muscle (PM) (n = 20) defined by
visually large PMs which occluded the LV cavity during systole or 1/2 LVESD, or as having a small LV cavity with
concentric remodelling or hypertrophy (n = 49). The prominent PM group was younger, had a higher S’ and lower
E/e’ than other groups. In all groups, a higher peak trans-LVOT PG was related (p < 0.10) to higher E/e’, systolic
blood pressure, relative wall thickness, and pulmonary arterial systolic pressure. In multivariate analysis, resting
trans-LVOT PG correlated to pulmonary arterial pressure (ß = 0.226, p = 0.019) after adjustment for systolic blood
pressure, relative wall thickness, and E/e’.
Conclusions: DLVOTO develops from various reasons, and patients with prominent PMs have distinct characteristics.
We suggest to use DLVOTO-relieving medication might reduce pulmonary pressure in this group of patients.
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Dynamic left ventricular (LV) outflow tract (LVOT) ob-
struction (DLVOTO) is not uncommonly observed in
aged individuals without overt hypertrophic cardiomyop-
athy (HCM) [1]. Any conditions which reduce LV cavity
size in combination with hypercontractility can induce
resting D LVOTO, or it can be provoked by preload ma-
nipulation or inotropic stimulation in what is termed la-
tent DLVOTO [1-4]. Aging is a well-matched condition* Correspondence: DRCLIFF@yuhs.ac; choi0928@yuhs.ac
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unless otherwise stated.to develop DLVOTO in terms of concentric remodelling
and basal septal bulging due to an increased angle to the
ascending aorta [5,6]. These echocardiographic cases
were frequently described simply as having a sigmoid
septum or basal septal hypertrophy without strict cri-
teria. However, even in this setting of ambiguous clinical
categorization, there are clearly diverse morphological
subtypes of outflow tract obstruction resulting from di-
verse etiologies. The geometrical determinants and clin-
ical implications have not been fully investigated.
Therefore, in this study, we sought to investigate associ-
ated geometric changes and classify DLVOTO subgroups
in detail and then evaluate their clinical characteristics.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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We retrospectively analysed echocardiographic images
diagnosed as DLVOTO with imaging obtained during
Valsalva maneuver from 2008 to 2012 in a single tertiary
referral hospital. DLVOTO was defined as a trans-LVOT
peak PG higher than 30 mmHg at resting or provoked
by a Valsalva maneuver, i.e., latent DLVOTO, in patients
without fixed structural stenosis (Figure 1). Patients were
excluded if they have classical HCM defined as asym-
metric septal hypertrophy extend to mid ventricle not
just confined to upper basal septum, septal to posterior
wall ratio >1.5, acute myocardial infarction, stress in-
duced cardiomyopathy, more than a moderate degree of
valvular heart disease, unstable hemodynamics which
might potentially induce transient-DLVOTO or poor
echocardiographic images. Also, we randomly selected
control group who had roughly similar age and gender
distribution, but not had DLVOTO and cardiovascular
disease, to study population in the same echo database
and analysed their echocardiographic images. Study pro-
tocols were approved by our institutional review board,
and informed consent from patients was waived due to
the retrospective nature of the study.
Conventional echocardiography with Valsalva maneuver
Each patient underwent a complete standard transtho-
racic echocardiography. The LV dimensions and septal
and posterior wall thickness were measured at end-
diastole and end-systole in the two-dimensional para-
sternal long axis or short axis views. LV ejection fractionFigure 1 Representative cases of DLVOTO with Doppler patterns at re
anterior motion (SAM) (A), a case with chordal SAM (B), and a case with pwas calculated using the modified Quinones’ method [7].
LV mass was measured by Devereux’s methods as rec-
ommended by the American Society of Echocardiog-
raphy [7]. Relative wall thickness was calculated as twice
the posterior wall thickness at end-diastole divided by
the LV end-diastolic dimension. The left atrial volume
was measured using the prolate ellipsoidal method at
the point of LV end-systole when the left atrial size was
maximal. From the apical window, a 1 mm pulsed Dop-
pler sample volume was placed at the mitral valve tip,
and mitral flow velocities from 5 to 10 cardiac cycles
were recorded. Peak early (E) and late (A) mitral inflow
velocities were also measured. Mitral annular velocity
was measured by tissue Doppler imaging using the
pulsed wave Doppler mode. The filter was set to exclude
high frequency signal, and the Nyquist limit was ad-
justed to a range of 15 to 20 cm/s. Gain and sample vol-
ume were minimized to allow for a clear tissue signal
with minimal background noise. Systolic (S’), early (e’)
and late diastolic velocities of the mitral annulus were
measured from the apical 4-chamber view with a 2- to
5-mm sample volume placed at the septal corner of
the mitral annulus. Peak velocity of tricuspid regurgita-
tion was measured and PASP was calculated as
4xTRV2 + RA pressure, where RA pressure was esti-
mated according to IVC diameter and its respiratory
variations [8]. In cases of systolic color flow acceler-
ation in the LVOT, trans-LVOT peak PG was mea-
sured with continuous wave Doppler both at rest and
during a Valsalva maneuver.st and during Valsalva maneuver. A case with leaflet systolic
rominent papillary muscles kissing to septum (C).
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Before echocardiography, all the patients underwent
blood pressure measurements in the upper arm with an
automatic sphygmomanometer (TM-2665P, AND, CA).
End-systolic systemic pressure was calculated as (2х sys-
tolic blood pressure + diastolic blood pressure)/3. The
left ventricular end-systolic meridional wall stress was
calculated by the method of Grossman et al. [9] Left
ventricular wall stress (g/cm2) at the end of systole was
calculated as (1.35)*(Pes)*(Des)/(4 )*(hes)*[l + (hes///Des)],
where Pes is the left ventricular pressure (mm Hg) at
end-systole determined by the end-systolic blood pres-
sure plus the end-systolic peak PG across the LVOT, Des
and h are the LV internal dimension and posterior wall
thickness (cm) at end-systole, respectively, 1.35 is a con-
version factor (mm Hg to g/cm), and 4 is a geometric
factor that results from conversion of the radius to the
internal dimension [10].
Measurements of LV geometry associated with DLVOTO
Interventricular basal septal thickness was measured at
end-diastole in apical 3-chamber view images. The angle
between the ascending aorta and the plane of the mitral
valvular orifice was measured at both end-diastole and
end-systole from 3-chamber views (Figure 2). Size of
papillary muscles was measured in patients with promin-
ent papillary muscle group in every imaging view. The
presence of systolic anterior motion (SAM) of mitral
valve and chordae was also reviewed from all the echo
images.
Statistical analysis
Clinical characteristics and echocardiographic parameters
are presented as mean ± standard deviation for continuous
variables and number (percentage) for categorical vari-
ables. Correlation analysis was performed between con-
tinuous variables using the Pearson correlation coefficient.
Comparisons of echocardiographic findings between
controls and study group were performed by independent
t-test. Comparison of clinical and echocardiographicFigure 2 Assessment of geometry-associated left ventricular outflow
diastole, the angle between the ascending aorta and the plane of the mitr
3-chamber view images.variables among subgroups was performed by ANOVA
with post-hoc analysis via Bonferroni correction. The
trans-LVOT-PG before and after a Valsalva maneuver was
compared using the paired t-test. Variables with p < 0.10
in univariate analysis were included in the multivariable
regression analysis. All the analyses were performed using
SPSS (version 20.0, IBM, USA), and p values less than
0.05 were considered significant.
Results
Baseline clinical and echocardiographic characteristics
Among 33,060 primary transthoracic echo reports, total
of 168 patients (0.5% of total primary cases) were stud-
ied after exclusion of cases with any exclusion criteria.
Referral reasons for echocardiography were evaluations
for chest pain or previous coronary artery disease in 27
(16%), ECG abnormalities in 15 (9%), dyspnea on exer-
tion in 21 (13%), and evaluation for origin of cardiac
murmur in 5 (3%), evaluation for target organ damage in
hypertension or diabetes in 93 (55%) or evaluation for
cause of syncope or dizziness in 7 (4%). Among them,
135 (80%) had latent DLVOTO. Mean age was 71 ±
11 years and 98 (58%) patients were women. One hundred
thirty-six patients (81%) had a history of hypertension and
54 (32%) had diabetes. The mean LV end-diastolic dimen-
sion and ejection fraction were 39.3 ± 4.6 mm and 69.0 ±
5.7%, respectively. The patients almost had no regional
wall motion abnormality except for few patients (n = 2).
The body surface area corrected LV end-diastolic dimen-
sional index (24.1 ± 3.1 mm/m2 vs. 26.7 ± 2.9 mm/m2, p <
0.001) and end-systolic dimensional index (15.3 ± 2.1 mm/
m2 vs. 17.5 ± 2.5 mm/2, p < 0.001) were significantly lower
than those of age- and sex- matched controls (n = 30).
Relative wall thickness was significantly higher than con-
trols (0.55 ± 0.10 vs. 0.46 ± 0.07, p < 0.001), suggesting sig-
nificant concentric remodelling. Baseline clinical and
echocardiographic variables are described in Table 1. The
basal septal thickness (17.2 ± 2.57 mm vs. 13.0 ± 1.6 mm,
p < 0.001) and the angle between the ascending aorta
and mitral annular plane (152.4 ± 12.3° vs. 145.6 ± 11.4°,tract obstruction. Measurements of basal septal wall thickness at end-
al valvular orifice at both end-diastole (A) and end-systole (B) from
Table 1 Baseline clinical and echocardiographic characteristics according to the presence of latent obstruction
Control Total Resting DLVOTO Latent DLVOTO §P
(n = 30) (n = 168) (n = 33) (n = 135)
Age, yrs 70.5 ± 1.7 71.0 ± 10.9 68.5 ± 10.4 71.7 ± 11.0 0.134
Women, n (%) 17 (57) 98 (58) 19 (58) 79 (59) 0.922
Hypertension, n (%) 14 (47) 136 (81) 25 (76) 111 (82) 0.397
Diabetes, n (%) 5 (17) 54 (32) 7 (21) 47 (35) 0.134
SBP, mmHg 136.3 ± 14.6 129.0 ± 20.7* 122.9 ± 17.6 130.3 ± 21.2 0.095
DBP, mmHg 78.8 ± 7.5 71.2 ± 11.8† 71.4 ± 13.4 71.2 ± 11.5 0.948
LVEDD, mm 42.8 ± 3.4 39.3 ± 4.6† 39.1 ± 5.3 39.3 ± 4.4 0.785
LVESD, mm 28.1 ± 3.0 25.0 ± 3.3† 24.7 ± 3.8 25.0 ± 3.2 0.635
LVEDD/BSA, mm/m2 26.7 ± 2.9 24.1 ± 3.1† 23.6 ± 3.5 24.2 ± 3.0 0.303
LVESD/BSA, mm/m2 17.5 ± 2.5 15.3 ± 2.1† 14.9 ± 2.5 15.4 ± 2.0 0.255
LV ejection fraction, % 66.5 ± 6.1 69.0 ± 5.7* 69.5 ± 5.9 68.9 ± 5.6 0.558
LV mass index, g/m2 85.7 ± 15.7 89.0 ± 25.9 94.0 ± 31.2 87.7 ± 24.4 0.290
BST, mm 1.30 ± 0.16 1.72 ± 0.26† 1.76 ± 0.24 1.72 ± 0.26 0.372
PWTd, mm 9.67 ± 1.24 10.62 ± 1.70* 11.09 ± 1.76 10.51 ± 1.67 0.077
PWTs, mm 13.43 ± 1.72 14.37 ± 1.86* 14.82 ± 2.13 14.26 ± 1.78 0.123
IVTd, mm 10.07 ± 1.44 11.46 ± 1.96† 11.97 ± 2.20 11.34 ± 1.88 0.096
IVTs, mm 13.43 ± 1.72 15.02 ± 2.20† 15.33 ± 2.16 14.95 ± 2.21 0.369
Relative wall thickness 0.45 ± 0.07 0.55 ± 0.10† 0.58 ± 0.11 0.54 ± 0.10 0.084
E/A ratio 0.79 ± 0.13 0.69 ± 0.37 0.72 ± 0.32 0.68 ± 0.38 0.615
E/e’ 10.1 ± 3.2 13.9 ± 5.1† 15.8 ± 7.1 13.6 ± 4.5 0.123
S’, cm/s 9.5 ± 1.3 8.4 ± 2.2 9.5 ± 3.3 8.1 ± 2.0 0.048
LA volume index, ml/m2 21.7 ± 5.3 25.6 ± 10.9* 27.5 ± 18.6 25.1 ± 8.0 0.480
LVESWS, g/cm2 57.1 ± 12.4 49.8 ± 13.0* 57.8 ± 16.9 48.0 ± 11.4 0.007
Any diuretics, n (%) 4 (13) 56 (33)* 12 (36) 44 (33) 0.680
CCB- dihydropyridine, n (%) 2 (7) 80 (48)† 17 (52) 63 (47) 0.398
CCBs-non-dihydropyrine, n (%) 0 (0) 7 (4)† 0 (0) 7 (4)
Any BBs, n (%) 2 (7) 44 (26)* 7 (21) 37 (27) 0.468
Angle at end-diastole, ° 145.6 ± 11.4 152.4 ± 12.3* 151.8 ± 11.9 152.5 ± 12.5 0.767
Angle at end-systole, ° 154.8 ± 11.6 162.2 ± 11.8* 162.1 ± 11.2 162.3 ± 12.0 0.933
Δ PG, mmHg 29.5 ± 17.5 29.1 ± 29.1 29.6 ± 15.3 0.946
PASP, mmHg 24.1 ± 5.3 28.8 ± 7.9* 32.2 ± 8.3 28.0 ± 7.6 0.007
*p < 0.05, †p < 0.01, §resting DLVOTO vs. latent DLVOTO, SBP, systolic blood pressure; DBP, diastolic blood pressure; LV, left ventricular; LVEDD, left ventricular end-
diastolic dimension; LVESD, left ventricular end-systolic dimension; BSA, body surface area; BST, basal septal thickness; PWTd, end-diastolic left ventricular posterior
wall thickness; LA, left atrial; LVESWS, left ventricular end-systolic wall stress; CCB, calcium channel blocker; BB, beta blocker; PG, pressure gradient.
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and sex-matched controls. The angle significantly in-
creased from 152.4 ± 12.3° at end-diastole to 162.2 ±
11.8° at end-systole (p < 0.001). The trans-LVOT peak
PG increased from 21.3 ± 19.8 mmHg to 46.9 ±
21.6 mmHg during a Valsalva maneuver. Basal septal
thickness at end-diastole was not significantly different
in hypertensive or diabetic patients compared to their
counterparts. Basal septal thickness did not correlate
with age, but the angle between the ascending aortaand mitral annular plane increased significantly with
age (r = 0.179, p = 0.02), and this relationship remained
significant after adjusting for hypertension, diabetes and
sex (ß = 0.240, p = 0.003).
Resting and latent DLVOTO
Patients with resting DLVOTO had higher LVESWS
(p = 0.007), lower S’ (p = 0.048) and a higher pulmon-
ary arterial systolic pressure (p = 0.007) than those with
latent DLVOTO. However, the prevalence of concomitant
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were not different. In the latent DLVOTO group, the
indexed LV end-diastolic dimension was inversely and sig-
nificantly correlated with an increase of the PG between
the resting state and the Valsalva maneuver (r = −0.224,
p = 0.01). However, other parameters such as angle and
basal septal thickness were not significantly correlated
with peak PG change.Morphologic classification related to DLVOTO
Study patients were classified as either having a pure sig-
moid septum, defined as basal septal bulging but dia-
stolic thickness ≤ 15 mm (n = 14); a sigmoid septum with
basal septal hypertrophy higher than 15 mm (n = 85); a
prominent papillary muscle (PM) (n = 20), defined as a
visually large PM which occlude the LV cavity during
systole or >1/2 LV end-systolic dimension and maximal
thickness of PM in short axis view higher than 11.2 mm
or longer than 2.6 cm in 2, 3 or 4 chamber view; or a
small LV cavity with concentric remodelling or hyper-
trophy (n = 49) (Figure 3). The prominent PM group was
younger, had a higher S’ and a lower E/e’ than other
groups. The frequency of beta-blocker usage was lower
in the prominent PM group. However, resting and
Valsalva-induced trans-LVOT peak PGs were not differ-
ent among subgroups (Table 2). Leaflets SAM was ob-
served in 31 patients (19%), chordal SAM in 80 (48%),
papillary muscle kissing to hypertrophied septum in 38
(23%), mixed type in 3 (2%) and non-above category was
in 16 (10%). Patients with leaflets SAM had higher res-
tign trans-LVOT PG. Analyses of their characteristics
are described in the Table 3.Figure 3 Representative case for each subgroup. Pure sigmoid septum
papillary muscle (C) and small LV cavity due to concentric remodelling (D)Clinical and hemodynamic impact of DLVOTO
In all groups, a higher peak trans-LVOT PG was corre-
lated to higher E/e’ (r = 0.246, p = 0.002), pulmonary ar-
terial systolic pressure (PASP, r = 0.317, p < 0.001),
systolic blood pressure (r = −0.142, p = 0.081) and rela-
tive wall thickness (r = 0.141, p = 0.070). In multivariate
analysis, resting trans-LVOT PG correlated to PASP (ß =
0.226, p = 0.019) after adjustment for systolic blood pres-
sure, relative wall thickness, and E/e’.Discussion
In this study, we found that, even in patients without
overt HCM, DLVOTO, especially the latent form, is not
infrequently seen in the absence of acute volume deple-
tion or hemodynamic instability. This group of patients
mainly has basal septal bulging and concentric remodel-
ling that is classically assumed to be an aging-related
change [11,12]. However, diverse morphological sub-
groups also exist. A significant portion of patients have
leaflets or chordal SAM. Of those subgroups, patients with
prominent PMs had distinct clinical and LV functional
characteristics suggesting a different etiology. In this group
of patients, a higher trans-LVOT PG results in a higher
pulmonary arterial pressure through diastolic dysfunction.
Thus, DLVOTO-relieving medication may potentially re-
duce pulmonary pressure in this group of patients.Diverse geometric changes related to DLVOTO
This group of patients had a small LV cavity and in-
creased basal septal thickness with a more angulated
ascending aorta compared to age- and sex-matched con-
trols. Classically, basal septal bulging due to focally(A), sigmoid septum with basal septal hypertrophy (B), prominent
.
Table 2 Comparisons of clinical and echocardiographic parameters among morphologically classified subgroups
Pure sigmoid septum Sigmoid septum with BSH Prominent PM Concentric remodelling
P
(n = 14) (n = 85) (n = 20) (n = 49)
Age, years 75.4 ± 9.5 72.3 ± 9.7 65.6 ± 9.7 69.9 ± 12.9 0.032
Women, n (%) 11 (79) 51 (60) 10 (50) 26 (53) 0.310
Hypertension, n (%) 14 (100) 70 (82) 16 (80) 36 (74) 0.158
Diabetes, n (%) 8 (57) 24 (28) 6 (30) 16 (33) 0.199
SBP, mmHg 124.9 ± 15.0 131.2 ± 21.0 125.3 ± 17.5 127.8 ± 22.7 0.550
DBP, mmHg 69.8 ± 10.2 72.3 ± 11.6 68.1 ± 12.9 71.0 ± 12.1 0.546
LVEDD, mm 38.7 ± 3.5 39.6 ± 4.2 39.7 ± 4.1 38.8 ± 5.7 0.742
LVESD, mm 25.4 ± 2.5 25.1 ± 3.0 25.8 ± 4.2 24.4 ± 3.6 0.361
LVEDD/BSA, mm/m2 24.9 ± 3.0 24.7 ± 3.1 22.9 ± 2.3 23.5 ± 3.1 0.028
LVESD/BSA, mm/m2 16.3 ± 1.8 15.6 ± 2.1 14.8 ± 2.0 14.7 ± 2.1 0.023
LV ejection fraction, % 66.9 ± 4.5 69.2 ± 5.7 67.9 ± 6.7 69.7 ± 5.4 0.298
Angle at end-systole, ° 166.4 ± 14.6 161.0 ± 12.1 164.2 ± 10.7 162.4 ± 10.7 0.356
Angle at end-diastole, ° 156.7 ± 13.4 151.3 ± 12.1 155.4 ± 12.5 151.7 ± 12.3 0.300
BST, mm 13.9 ± 1.1 18.3 ± 2.1 14.9 ± 1.4 17.4 ± 2.5 <0.001
LVMI, g/m2 74.4 ± 16.7 92.1 ± 25.3 77.2 ± 13.8 92.6 ± 30.2 0.012
LA volume index, ml/m2 27.3 ± 8.3 27.0 ± 13.0 21.9 ± 5.9 24.1 ± 8.4 0.176
E/e’ 14.6 ± 5.4 14.3 ± 4.9 10.9 ± 3.3 14.5 ± 5.6 0.042
S’, cm/s 8.1 ± 2.0 8.3 ± 2.0 10.0 ± 3.1 7.8 ± 2.0 0.004
Latent DLVOTO, n (%) 14 (100) 16 (78) 17 (85) 38 (78) 0.227
LVOT PGresting, mmHg 14.8 ± 7.0 23.2 ± 23.1 17.5 ± 13.1 21.6 ± 18.0 0.393
LVOT PGValsalva, mmHg 43.2 ± 11.8 47.4 ± 25.1 46.2 ± 13.7 47.4 ± 20.4 0.919
ΔPG, mmHg 28.4 ± 16.3 29.5 ± 18.8 30.6 ± 12.3 29.4 ± 18.0 0.988
LVESWS, g/cm 53.9 ± 10.4 51.9 ± 14.1 51.1 ± 14.3 44.5 ± 9.8 0.011
DLVOTO, dynamic left ventricular outflow tract obstruction; See abbreviations in Table 1.
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aorta angle [11] with concentric LV remodelling [12] has
been accepted as part of the aging process. Although the
high prevalence of hypertension in the enrolled patients
is possibly due to referral bias, basal septal thickness and
aortic-angle were not different between hypertensive pa-
tients and their counterparts, which suggests that hyper-
tension is not the main cause of DLVOTO related
changes of LV geometry. Gender predominance was not
observed. Our study also supports the finding that age is
significantly correlated with the degree of aortic-
angulation. This change is usually termed either sigmoid
septum or basal septal hypertrophy, resulting in some
confusion. Some previous reports have described basal
septal hypertrophy as a subtype of HCM [13]. According
to the results of this study, basal septal hypertrophy does
not result in a difference in clinical characteristics com-
pared to a purely sigmoid septal outflow tract obstruc-
tion. This is in contrast to the differences seen in the
prominent PM group, suggesting that basal septal hyper-
trophy is more likely an aging-related change rather than
a subtype of HCM. The current study also supportsprevious studies which showed that hypertrophied PMs
were related to DLVOTO in the absence of LV hyper-
trophy [14]. To prevent misdiagnosis, when DLVOTO is
detected, both an age-related sigmoid septum and PM
hypertrophy should be considered. Thorough evaluation
for the possibility of HCM might be needed in this sub-
group. This distinction also suggests that basal septal
hypertrophy is less likely to be a subtype of HCM. An-
other interesting finding is lots of patients had SAM or
chordal SAM in this population, which is consistent with
previous observation [15]. Therfore LV geometric change
in combination with abnormal mitral apparatus abnor-
malities such as systolic movement of mitral leaflets,
chordae and papillary muscle may contribute develop-
ments of DLVOTO [16,17].
Clinical and hemodynamic characteristics of DLVOTO
Elderly people frequently complain of dyspnea on exer-
tion due to diastolic dysfunction and reactive pulmonary
venous hypertension. Therefore, aging is thought to be
the leading cause of heart failure with a preserved ejec-
tion fraction [18]. The usual treatment for this group of
Table 3 Classification according to presence or patterns of systolic anterior motion of mitral valve
Leaflet SAM Chordal SAM PM kissing Mixed None of above
P
(n = 31) (n = 80) (n = 38) (n = 3) (n = 16)
Age, years 71.4 ± 11.0 72.2 ± 9.6 67.2 ± 13.5 69.3 ± 17.8 74.1 ± 7.5 0.140
Women, n (%) 18 (13) 27 (34) 14 (37) 2 (67) 9 (56) 0.091
Hypertension, n (%) 20 (65) 67 (84) 34 (90) 2 (67) 13 (81) 0.091
SBP, mmHg 123.9 ± 17.2 130.8 ± 19.4 131.6 ± 23.6 120.0 ± 5.7 123.7 ± 26.5 0.409
DBP, mmHg 71.8 ± 11.3 71.4 ± 11.3 72.8 ± 13.4 71.0 ± 8.5 64.7 ± 10.3 0.320
LVEDD/BSA, mm/m2 23.8 ± 2.7 24.4 ± 2.7 23.6 ± 3.2 28.0 ± 9.8 24.3 ± 4.3 0.255
LVESD/BSA, mm/m2 15.0 ± 2.3 15.6 ± 2.0 14.9 ± 2.1 17.2 ± 4.3 15.2 ± 2.4 0.271
LV ejection fraction, % 70.3 ± 5.1 68.1 ± 5.8 69.5 ± 5.7 71.0 ± 7.1 69.6 ± 5.9 0.355
Angle at end-systole, ° 160.3 ± 9.9 161.2 ± 11.9 165.5 ± 12.4 162.2 ± 11.4 163.5 ± 13.0 0.338
Angle at end-diastole, ° 151.3 ± 10.0 151.1 ± 12.8 154.8 ± 13.2 150.6 ± 10.1 155.0 ± 12.1 0.505
BST, mm 15.7 ± 2.5 15.6 ± 2.7 14.1 ± 2.0 15.9 ± 3.3 15.7 ± 1.7 0.024
LVMI, g/m2 96.4 ± 30.8 87.5 ± 20.4 87.1 ± 24.1 86.4 ± 30.2 86.7 ± 40.9 0.540
LA volume index, ml/m2 27.6 ± 18.8 24.2 ± 7.2 27.0 ± 7.8 34.1 ± 17.6 24.0 ± 10.9 0.340
E/e’ 15.0 ± 5.5 14.0 ± 5.2 13.4 ± 4.4 13.1 ± 6.1 12.6 ± 0.6 0.716
S’, cm/s 8.5 ± 2.3 8.1 ± 1.8 8.4 ± 2.6 6.0 ± 1.4 9.7 ± 3.1 0.076
Latent DLVOTO, n (%) 16 (52) 74 (93) 32 (84) 3 (100) 10 (63) <0.001
LVOT PGresting, mmHg 36.7 ± 28.8 15.6 ± 15.0 18.3 ± 14.3 12.6 ± 6.3 27.1 ± 15.8 <0.001
LVOT PGValsalva, mmHg 64.3 ± 39.9 43.4 ± 13.9 42.7 ± 13.0 41.4 ± 20.4 45.3 ± 11.3 <0.001
LVESWS, g/cm 52.1 ± 15.5 49.8 ± 13.1 48.7 ± 10.6 38.7 ± 4.8 49.2 ± 14.0 0.633
SAM, systolic anterior motion of mitral valve. See abbreviations in the Tables 1 and 2.
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these patients respond well to diuretics, and some patients
suffer from significant orthostatic hypotension [19]. In this
regard, the patients enrolled in this study share similar risk
factors for the development of heart failure with preserved
ejection such as aging, a higher prevalence of hyperten-
sion, and diastolic dysfunction with concentric remodel-
ling [20]. Although LV ejection fraction was significantly
higher in DLVOTO group compared to control, trans-
LVOT- PG was not significantly correlated to LV ejection
fraction. Therefore, geometrical change around LVOT
might be stronger determinants than LV ejection fraction
for degree of DLVOTO. According to this study, a higher
trans-LVOT PG was associated with a higher pulmonary
arterial pressure, so particular attention should be paid
when selecting medications in this group of patients. In
this regard, beta blockers or non-dihydropyridine-based
calcium channel blockers, rather than diuretics, can im-
prove symptoms and outcomes. This group of patients
would be a potential subgroup of heart failure with pre-
served ejection fraction. Therefore, their managements
should be individualized.
Study limitations
This study has several limitations. First, due to the na-
ture of this retrospective study performed in a tertiary
referral hospital, there may be some referral bias, andthe actual prevalence of concomitant risk factors could
not be truly measured. Additionally, Valsalva maneuver
was not routinely done in all patients but only in patients
with color flow turbulence or acceleration at rest in our
echo-lab, the actual prevalence of latent DLVOTO might
be underestimated. Secondly, although patients with sec-
ondary DLVOTO related to HCM or other conditions
were excluded, complete evaluation by invasive hemo-
dynamic status was not performed. Thirdly, classification
based on basal septum thickness, LV concentric remodel-
ling and visually assessed PM morphology is somewhat ar-
bitrary. However, individual subtypes have been reported
in previous studies [5,11,14], so the application of a novel
classification system to this study group seems appropriate.Conclusions
DLVOTO can develop due to various geometric changes,
but patients with a prominent PM have distinct character-
istics suggestive of atypical HCM rather than age-related
changes. A higher trans-LVOT PG results in a higher pul-
monary arterial pressure through diastolic dysfunction.
Therefore, LVOTO-relieving medication might reduce the
occurrence or severity of symptoms by reducing pulmon-
ary pressure in this group of patients.
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